Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04986670 | NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer | active not recruiting | N/A | 299 | Tufts UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT05949619 | A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 14 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05020457 | SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC. | active not recruiting | Phase 2 | 69 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05020769 | SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer. | active not recruiting | Phase 2 / Phase 3 | 14 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05163028 | A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations | active not recruiting | Phase 1 | 42 | HUYABIO International, LLC.INDUSTRY | 2 | Sep 24, 2025 | clinicaltrials |
| NCT05485974 | A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation | active not recruiting | Phase 1 | 44 | HUYABIO International, LLC.INDUSTRY | 2 | Sep 24, 2025 | clinicaltrials |
| NCT06448910 | Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC | active not recruiting | Phase 2 | 41 | Fudan UniversityOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT03289780 | Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects(INSIGHT) | active not recruiting | — | 5,006 | Biodesix, Inc.INDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT05880706 | A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 198 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06205706 | BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 4 | Sep 19, 2025 | clinicaltrials |
| NCT02788461 | Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy(PET-BOOST) | active not recruiting | N/A | 78 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT03306680 | SUNSET: SBRT for Ultra-central NSCLC- a Safety and Efficacy Trial | active not recruiting | Phase 1 | 30 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT03485378 | Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease(ASPIRE-ILD) | active not recruiting | N/A | 39 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 2 | Sep 18, 2025 | clinicaltrials |
| NCT04547504 | PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %(PERSEE) | active not recruiting | Phase 3 | 349 | University Hospital, BrestOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT03647163 | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 33 | Vyriad, Inc.INDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT06020066 | SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI | active not recruiting | Phase 2 | 202 | Fudan UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT02617186 | Robotic Lobectomy vs. Thoracoscopic Lobectomy for Early Stage Lung Cancer: RCT | active not recruiting | N/A | 446 | St. Joseph's Healthcare HamiltonOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT05091190 | Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers(MADMAS) | active not recruiting | N/A | 75 | Hospices Civils de LyonOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05653882 | A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | active not recruiting | Phase 1 | 552 | Asher Biotherapeutics, Inc.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT04946279 | Decision Aid for the Improvement of Decision-Making in Patients With Non-small Cell Lung Cancer | active not recruiting | N/A | 98 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05318573 | A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 120 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT05585320 | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 209 | Immuneering CorporationINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06505837 | JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC） | active not recruiting | Phase 3 | 395 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT03907852 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | TCR2 TherapeuticsINDUSTRY | 2 | Aug 27, 2025 | clinicaltrials |
| NCT04495153 | CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC | active not recruiting | Phase 2 | 90 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 914 | ExelixisINDUSTRY | 9 | Aug 17, 2025 | clinicaltrials |
| NCT03620669 | 1st Line Durvalumab in PS 2 NSCLC Patients | active not recruiting | Phase 2 | 48 | Swiss Cancer InstituteOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT05787613 | A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients | active not recruiting | Phase 2 | 132 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
| NCT05049044 | Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)(OBSTINATE) | active not recruiting | — | 413 | Groupe Francais De Pneumo-CancerologieOTHER | 1 | Aug 4, 2025 | clinicaltrials |
| NCT05078931 | A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients | active not recruiting | Phase 2 | 35 | Shanghai Chest HospitalOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06105021 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 100 | Affini-T Therapeutics, Inc.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT03753685 | X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases | active not recruiting | Phase 2 | 27 | Fudan UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05894889 | Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC | active not recruiting | Phase 2 | 70 | Peking UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07076693 | Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC） | active not recruiting | Phase 2 / Phase 3 | 97 | Shanghai Chest HospitalOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05195619 | Personalized DC Vaccines in Non Small Cell Lung Cancer | active not recruiting | Phase 1 | 16 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT02284308 | Elderly With Locally Advanced Lung Cancer: Deciding Through Geriatric Assessment on the Optimal Treatment Strategy(ELDAPT) | active not recruiting | — | 180 | Maastricht Radiation OncologyOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT05286294 | Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders(MITRIC) | active not recruiting | Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT05943795 | A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma | active not recruiting | Phase 3 | 589 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 29, 2025 | clinicaltrials |
| NCT04175769 | A Nutritional Supplement to Support People With Non-small Cell Lung Cancer | active not recruiting | N/A | 9 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT05116462 | Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer | active not recruiting | Phase 3 | 506 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04676477 | HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 246 | Daiichi SankyoINDUSTRY | 4 | Jun 22, 2025 | clinicaltrials |
| NCT05607550 | Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) | active not recruiting | Phase 3 | 398 | ArriVent BioPharma, Inc.INDUSTRY | 19 | Jun 22, 2025 | clinicaltrials |
| NCT07024862 | Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy | active not recruiting | — | 100 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 17, 2025 | clinicaltrials |
| NCT05180799 | A Phase 1/2 Study of BA3071 in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 320 | BioAtla, Inc.INDUSTRY | 2 | Jun 15, 2025 | clinicaltrials |
| NCT04533451 | Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 101 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT04027647 | Phase 2 Study of Dacomitinib in NSCLC | active not recruiting | Phase 2 | 118 | National Cancer Centre, SingaporeOTHER | 5 | Jun 12, 2025 | clinicaltrials |
| NCT05319574 | SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer(SACTION01) | active not recruiting | Phase 2 | 46 | Sun Yat-sen UniversityOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT03800134 | A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer(AEGEAN) | active not recruiting | Phase 3 | 825 | AstraZenecaINDUSTRY | 28 | Jun 11, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 30, 2025source: clinicaltrials